A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Authors:
- Jasvinder A. SinghJSJasvinder A. Singh
- Robin ChristensenRCRobin Christensen
- George A. WellsGWGeorge A. Wells
- Maria E. Suarez-AlmazorMSMaria E. Suarez-Almazor
- Rachelle BuchbinderRBRachelle Buchbinder
- Maria Angeles Lopez-OlivoMLMaria Angeles Lopez-Olivo
- Elizabeth Tanjong GhogomuEGElizabeth Tanjong Ghogomu
- Peter TugwellPTPeter Tugwell
- 2 November 2009
- journal article
- research article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 181 (11) , 787-796
Abstract
Background: We sought to compare the benefits and safety of 6 biologics (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab) in patients with rheumatoid arthritis. Methods: In this network meta-analysis, we included all completed and updated Cochrane reviews on biologics for rheumatoid arthritis. We included data from all placebo-controlled trials that used standard dosing regimens. The major outcomes were benefit (defined as a 50% improvement in patient- and physician-reported criteria of the American College of Rheumatology [ACR50]) and safety (determined by the number of withdrawals related to adverse events). We used mixed-effects logistic regression to carry out an indirect comparison of the treatment effects between biologics. Results: Compared with placebo, biologics were associated with a clinically important higher ACR50 rate (odds ratio [OR] 3.35, 95% confidence interval [CI] 2.62–4.29) and a number needed to treat for benefit of 4 (95% CI 4–6). However, biologics were associated with more withdrawals related to adverse events (OR 1.39, 95% CI 1.13–1.71), with a number needed to treat for harm of 52 (95% CI 29–152). Anakinra was less effective than all of the other biologics, although this difference was statistically significant only for the comparison with adalimumab (OR 0.45, 95% CI 0.21–0.99) and etanercept (OR 0.34, 95% CI 0.14–0.81). Adalimumab, anakinra and infliximab were more likely than etanercept to lead to withdrawals related to adverse events (adalimumab OR 1.89, 95% CI 1.18–3.04; anakinra OR 2.05, 95% CI 1.27–3.29; and infliximab OR 2.70, 95% CI 1.43–5.26). Interpretation: Given the limitations of indirect comparisons, anakinra was less effective than adalimumab and etanercept, and etanercept was safer than adalimumab, anakinra and infliximab. This summary of the evidence will help physicians and patients to make evidence-based choices about biologics for the treatment of rheumatoid arthritis.Keywords
This publication has 52 references indexed in Scilit:
- The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnnals of the Rheumatic Diseases, 2009
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2008
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskeletal Disorders, 2008
- Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE studyModern Rheumatology, 2008
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals of the Rheumatic Diseases, 2007
- Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacitiesAnnals of the Rheumatic Diseases, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritisStatistics in Medicine, 2006
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988